Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Molecular imaging in oncology: Current impact and future directions
The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …
Molecular Imaging, as the visualization, characterization, and measurement of biological …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …
Background Conventional imaging using CT and bone scan has insufficient sensitivity when
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
staging men with high-risk localised prostate cancer. We aimed to investigate whether novel …
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …
E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET
Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
Using PSMA imaging for prognostication in localized and advanced prostate cancer
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, hel** to …
prostate cancer management has evolved rapidly over the past few years, hel** to …
[HTML][HTML] Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …